Does malarial tolerance, through nitric oxide, explain the low incidence of autoimmune disease in tropical Africa?

Lancet

Volumn 348, Issue 9040, 1996, Pages 1492-1494

  Clark, I A ^a   Al Yaman, F M ^a   Cowden, W B ^b   Rockett, K A ^c  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Biology and Environment   (Australia)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NITRATE; NITRIC OXIDE; NITRITE;

AFRICA; ARTICLE; AUTOIMMUNITY; BLOOD LEVEL; BRAIN MALARIA; CELL PROLIFERATION; EPIDEMIOLOGY; HUMAN; HYPERTENSION; INCIDENCE; MACROPHAGE; MALARIA; NONHUMAN; PRIORITY JOURNAL; RURAL POPULATION; T LYMPHOCYTE; TROPICS;

EID: 0030607604     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07342-4     Document Type: Note

References (28)

1. 1 Greenwood BM. Autoimmune disease and parasitic infections in Nigerians. Lancet 1968; ii: 380-82.
2. 2 Clark IA, Rockett KA, Cowden WB. Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 1992; 340: 894-96.
3. 3 Nussler AK, Eling W, Kremsner PG. Patients with Plasmodium falciparum malaria and Plasmodium vivax malaria show increased nitrite and nitrate plasma levels. J Infect Dis 1994; 169: 1418-19.
4. 4 Al Yaman F, Genton B, Mokela D, et al. Association between serum levels of reactive nitrogen intermediates and coma in children with cerebral malaria in Papua New Guinea. Trans R Soc Trop Med Hyg 1996; 90: 270-73.
5. 5 Anstey NM, Weinberg JB, Hassanali M, et al. Nitric oxide in Tanzanian children with malaria: inverse relationship between malaria severity and nitric oxide production/nitric oxide synthase type 2 expression. J Exp Med 1996; 184: 557-67.
6. 6 Al-Yaman F, Awburn M, Clark IA. Serum creatinine levels and reactive nitrogen intermediates in children with cerebral malaria in Papua New Guinea. Trans R Soc Trop Med Hyg (in press).
7. 7 Murray HW, Teitelbaum RF. L-arginine dependent reactive nitrogen intermediates and the antimicrobial effect of activated human mononuclear phagocytes. J Infect Dis 1992; 165: 513-17.
8. 8 Weinberg JB, Misukonis MA, Shami PJ, et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995; 86: 1184-95.
9. 9 Kremsner PG, Winkler S, Wildling E, et al. High plasma levels of nitrogen oxides are associated with severe disease and correlate with rapid parasitological and clinical cure in plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1996; 90: 44-47.
10. 10 Kitchen SF. Falciparum malaria. In: Boyd MF, ed. Malariology. Philadelphia: WB Saunders, 1949: 966-94.
11. 11 Rubenstein M, Mulholland JH, Jeffery GM, et al. Malaria-induced endotoxin tolerance. Proc Soc Exp Biol Med 1965; 118: 238-87.
12. 12 Bate CAW, Taverne J, Dave A, et al. Malaria exoantigens induce T-independent antibody that blocks their ability to induce TNF. Immunology 1990; 70: 315-20.
13. 13 Ziegler-Heitbrock HWL. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm 1995; 45: 13-26.
14. 14 Fahmi H, Charon D, Mondange M, et al. Endotoxin-induced desensitization of mouse macrophages is mediated in part by nitric oxide production. Infect Immun 1995; 63: 1863-69.
15. 15 Zingarelli B, Halushka PV, Caputi AP, et al. Increased nitric oxide synthesis during the development of endotoxin tolerance. Shock 1995; 3: 102-08.
16. 16 Rojas A, Padron J, Caveda L, et al. Role of nitric oxide pathway in the protection against lethal endotoxemia afforded by low doses of lipopolysaccharide. Biochem Biophys Res Commun 1993; 191: 441-46.
17. 17 Williamson WA, Greenwood BM. Impairment of the immune response to vaccination after acute malaria. Lancet 1978; i: 1328-29.
18. 18 Taylor DW, Siddiqui WA. Effect of falciparum malaria infection on the in vitro mitogen responses of spleen and peripheral blood lymphocytes from owl monkeys. Am J Trop Med Hyg 1978; 27: 738-42.
19. 19 Mills CD. Molecular basis of "suppressor" macrophages: arginine metabolism via the nitric oxide synthetase pathway. J Immunol 1991; 146: 2719-23.
20. 20 Rockett KA, Awburn MM, Rockett EJ, et al. Possible role of nitric oxide in malarial immunosuppression. Parasite Immunol 1994; 16: 243-49.
21. 21 Ruuls SR, Vanderlinden S, Sontrop K, et al. Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin Exp Immunol 1996; 103: 467-74.
22. 22 von Muller CS, Spitler LE, LeCocq J. Experimental allergic encephalitis: study of cellular immunity during disease suppression. Eur J Immunol 1978; 8: 771-76.
23. 23 Sternberg J, McGuigan F. Nitric oxide mediates suppression of T-cell responses in murine Trypanosoma brucei infection. Eur J Immunol 1992; 22:2741-44.
24. 24 Isobe KI, Nakashima I. Feedback suppression of staphylococcal enterotoxin-stimulated lymphocyte-T proliferation by macrophages through inductive nitric oxide synthesis. Infect Immun 1992; 60: 4832-37.
25. 25 Johnson AE, Gordon C, Palmer RG, et al. The prevalence and incidence of systemic lupus erythematosus in Birmingham, England. Arthritis Rheum 1995; 38: 551-58.
26. 26 Powell RD, McNamara JD, Reickman KH. Clinical acquisition of immunity to falciparum malaria. Proc Helminth Soc Wash 1972; 39: 51-66.
27. 27 Scammell TE, Elmquist JK, Saper CB. Inhibition of nitric oxide synthase produces hypothermia and depresses lipopolysaccharide fever. Am J Physiol 1996; 40: R333-38.
28. 28 Rutledge DR. Race and hypertension: what is clinically relevant? Drugs 1994; 47: 914-32.